Retina Gallery ~ Full Sized Retina Images

Library of Free, Non-Copyrighted Retina Images and Videos

Choose your language:
Last additions

Genetic_Testing_-Cohen_Patient-1.jpg
ABCA4 positive - Stargardt Disease5 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.

PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21
Jan 16, 2022
ABCA_sycai_010722_10.jpg
ABCA4 positive - Stargardt Disease6 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.

PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21
Jan 16, 2022
ABCA_sycai_010722_09.jpg
ABCA4 positive - Stargardt Disease5 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.

PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21
Jan 16, 2022
ABCA_sycai_010722_08.jpg
ABCA4 positive - Stargardt Disease0 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.

PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21
Jan 16, 2022
ABCA_sycai_010722_07.jpg
ABCA4 positive - Stargardt Disease1 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.

PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21
Jan 16, 2022
ABCA_sycai_010722_06.jpg
ABCA4 positive - Stargardt Disease2 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.

PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21
Jan 16, 2022
ABCA_sycai_010722_01.jpg
ABCA4 positive - Stargardt Disease1 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.

PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21
Jan 16, 2022
ABCA_sycai_010722_02.jpg
ABCA4 positive - Stargardt Disease0 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.

PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21
Jan 16, 2022
ABCA_sycai_010722_05.jpg
ABCA4 positive - Stargardt Disease1 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.

PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21
Jan 16, 2022
ABCA_sycai_010722_04.jpg
ABCA4 positive - Stargardt Disease0 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.

PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21
Jan 16, 2022
ABCA_sycai_010722_03.jpg
ABCA4 positive - Stargardt Disease0 views24 year old female She has worn glasses since she was a kid. Since she became an adult her vision started to deteriorate more rapidly. This seems to have been happening since she entered the accounting department for the last two years. Her vision is worse in the light especially when she is driving. She can see green lights in the night but not in the day. She sees better on a dark background than on a light background.
Her mother and father both have inherited retinal diseases. His mother was diagnosed 23 years ago with Stargardts genetically confirmed in Boston. The father has Retinitis Pigmentosa. The mother has seven brothers and sisters and four have Stargardts and they are legally blind. Also one cousin has it.

PMHx benign, Meds: vitamins.
VA OD: Dcc20/160
VA OS: Dcc20/160
IOP: TP: OD:20 OS:21
Jan 16, 2022
Color_WF_20211227170915_OS_20220106091817_-0_719999969005585_0_28229.jpg
Ocular lymphoma - better following intravitreal methotrexate14 viewsVA improved from LP to 20/200 after 4 injections of methotrexateJan 06, 2022
Color_WF_20211206111829_OS_20220106091816_-0_100000016391277_0_28229.jpg
Ocular Lymphoma - Flare up despite chemotherapy and radiation therapy - This was treated with intravitreal methotrexate12 viewsVision in the left eye has declined to LP in this image following ocular recurrence of lymphomaJan 06, 2022
bdump_dastr_20211227_40.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)12 views67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32
Jan 06, 2022
bdump_dastr_20211227_42.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32
Jan 06, 2022
bdump_dastr_20211227_39.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32
Jan 06, 2022
bdump_dastr_20211227_41.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/32
Jan 06, 2022
bdump_dastr_20211111_36.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211111_35.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211111_38_28229.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)2 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211111_37_28229.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_34.png
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_33.png
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_32.png
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_31.png
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_04.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_30.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_29.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_28.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_27.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_26.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_25.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_24.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_23.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_22.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_21.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_20.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_19.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)5 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_18.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_17.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_16.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_15.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_14.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_13.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_12.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_11.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)2 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_02.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)3 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_10.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)7 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_09.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)7 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_08.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)4 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_07.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)7 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_06.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)6 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_05.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)6 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_01.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)6 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
bdump_dastr_20211004_03.jpg
Bilateral Diffuse Melanocytic Proliferation (BDUMP)7 views67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.
Jan 06, 2022
Lattice-2_months_post_laser_28129.jpg
Lattice with tears - 3 months post-laser45 viewsDec 13, 2021
Lattice-2_months_post_laser_28229.jpg
Lattice with tears - 3 months post-laser40 viewsDec 13, 2021
BRVO-withMA-maps_28129.JPG
Old BRVO with venous MA - post-laser OCT Maps98 viewsOct 29, 2021
BRVO-withMA-maps_28229.JPG
Old BRVO with venous MA - post-laser OCT Maps73 viewsOct 29, 2021
NPDR_edhal_092821_24.jpg
Nonproliferative Diabetic Retinopathy and Good Vision66 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_23.jpg
Nonproliferative Diabetic Retinopathy and Good Vision6 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_22.jpg
Nonproliferative Diabetic Retinopathy and Good Vision6 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_21.jpg
Nonproliferative Diabetic Retinopathy and Good Vision10 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_20.jpg
Nonproliferative Diabetic Retinopathy and Good Vision9 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_19.jpg
Nonproliferative Diabetic Retinopathy and Good Vision12 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_18.jpg
Nonproliferative Diabetic Retinopathy and Good Vision10 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_17.jpg
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_16.jpg
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_15.jpg
Nonproliferative Diabetic Retinopathy and Good Vision7 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_14.jpg
Nonproliferative Diabetic Retinopathy and Good Vision9 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_13.jpg
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_12.jpg
Nonproliferative Diabetic Retinopathy and Good Vision7 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_07.JPG
Nonproliferative Diabetic Retinopathy and Good Vision7 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_11.jpg
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_10.jpg
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_09.jpg
Nonproliferative Diabetic Retinopathy and Good Vision10 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_08.jpg
Nonproliferative Diabetic Retinopathy and Good Vision9 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_06.jpg
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_01.jpg
Nonproliferative Diabetic Retinopathy and Good Vision22 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_02.jpg
Nonproliferative Diabetic Retinopathy and Good Vision9 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_05.jpg
Nonproliferative Diabetic Retinopathy and Good Vision13 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_04.jpg
Nonproliferative Diabetic Retinopathy and Good Vision8 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
NPDR_edhal_092821_03.jpg
Nonproliferative Diabetic Retinopathy and Good Vision9 views59 year old man Vision is good. Just referred following annual eye examination
PMHx: Type II DM, HTN, Cholesterol,
MEDS: Lantus, Metformin, lisinopril, atorvastatin, gabapentin

VA 20/20 OU
2+ NS OU

Observation
Oct 29, 2021
Iris_cyst_robra_012021_05.JPG
Idiopathic Iris Cyst16 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and others
Oct 28, 2021
Iris_cyst_robra_012021_06.JPG
Idiopathic Iris Cyst14 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and others
Oct 28, 2021
Iris_cyst_robra_012021_04.JPG
Idiopathic Iris Cyst15 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and others
Oct 28, 2021
Iris_cyst_robra_012021_01.jpg
Idiopathic Iris Cyst9 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and others
Oct 28, 2021
Iris_cyst_robra_012021_02.jpg
Idiopathic Iris Cyst9 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and others
Oct 28, 2021
Iris_cyst_robra_012021_03.jpg
Idiopathic Iris Cyst12 views85 year old man History of wet AMD OD x 7 years under treatment with Lucentis. VA 20/40 OD, 20/32 OS
PMHx High cholesterol, GERD, COPD, A-Fib,
MEDS: coumadin and ASA and others
Oct 28, 2021
non-exudative-CNVM-mafly_2019-2021_11.jpg
Non-exudative wet AMD - OCT angiogram12 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16
Oct 28, 2021
non-exudative-CNVM-mafly_2019-2021_10.jpg
Non-exudative wet AMD - OCT angiogram12 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16
Oct 28, 2021
non-exudative-CNVM-mafly_2019-2021_09.JPG
Non-exudative wet AMD - OCT angiogram8 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16
Oct 28, 2021
non-exudative-CNVM-mafly_2019-2021_08.JPG
Non-exudative wet AMD - OCT angiogram9 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16
Oct 28, 2021
non-exudative-CNVM-mafly_2019-2021_07.JPG
Non-exudative wet AMD - OCT angiogram8 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16
Oct 28, 2021
non-exudative-CNVM-mafly_2019-2021_06.jpg
Non-exudative wet AMD - OCT angiogram9 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16
Oct 28, 2021
non-exudative-CNVM-mafly_2019-2021_05.jpg
Non-exudative wet AMD - OCT angiogram9 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16
Oct 28, 2021
non-exudative-CNVM-mafly_2019-2021_04.jpg
Non-exudative wet AMD - OCT angiogram6 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16
Oct 28, 2021
non-exudative-CNVM-mafly_2019-2021_02.jpg
Non-exudative wet AMD - OCT angiogram8 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16
Oct 28, 2021
non-exudative-CNVM-mafly_2019-2021_01.jpg
Non-exudative wet AMD - OCT angiogram8 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16
Oct 28, 2021
non-exudative-CNVM-mafly_2019-2021_03.jpg
Non-exudative wet AMD - OCT angiogram13 views85 year old female with minimal visual complaints.
VA OD: sc20/80+1 PHNI NccJ3
VA OS: sc20/40-2 PH20/32+1 NccJ3
IOP: TP: OD:14 OS:16
Oct 28, 2021
14607 files on 147 page(s) 1